 Exact Sciences Corps NASDAQ: EXAS Q4 revenues increased 2 YY to 473.8 million and beat the average Wall Street estimate of 449 million. Excluding COVID-19 testing revenues, which dropped 52 to 47.1 million, Exacts Q4 revenue increased 16. 